|

Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

RECRUITINGSponsored by Tongji Hospital
Actively Recruiting
SponsorTongji Hospital
Started2021-12-31
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05541367

Summary

18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor（ER）-positive tumors . 18F-FES has been used as a predictive biomarker to demonstrate estrogen receptor heterogeneity , to evaluate the pharmacokinetics of estrogen receptor-targeted drugs ， to measure residual estrogen receptors during endocrine therapy and to determine biologically optimal doses of novel estrogen receptor-targeted drugs .This study aimes to explore the efficacy of 18F-FES PET/CT in evaluating the expression levels of ER in primary and metastatic breast cancer patients.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* More than 18 years old
* Patients with pathologically confirmed breast cancer
* Sign the informed consent form

Exclusion Criteria:

* Pregnant women
* Severe underlying diseases that cannot cooperate with PET examination

Conditions4

Breast CancerCancerEstrogen-receptor-negative Breast CancerTNBC - Triple-Negative Breast Cancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.